Quick Answer
Akebia Therapeutics, Inc. reported Operating Income of $23.50 million for fiscal year 2025.
Akebia Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $23.50M | +146.6% |
| 2024 | -$50.47M | -9.1% |
| 2023 | -$46.26M | +42.7% |
| 2022 | -$80.78M | +69.6% |
| 2021 | -$265.32M | +29.5% |
| 2020 | -$376.44M | -31.5% |
| 2019 | -$286.29M | -60.7% |
| 2018 | -$178.16M | -132.4% |
| 2017 | -$76.67M | +43.8% |
| 2016 | -$136.46M | -121.8% |
| 2015 | -$61.51M | -62.1% |
| 2014 | -$37.94M | -138.1% |
| 2013 | -$15.93M | -86.9% |
| 2012 | -$8.52M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.45M | +135.6% | -68.4% |
| June 30, 2025 | $14.09M | +261.5% | +4.3% |
| March 31, 2025 | $13.51M | +190.5% | +208.1% |
| September 30, 2024 | -$12.51M | +4.1% | -43.3% |
| June 30, 2024 | -$8.72M | +3.0% | +41.6% |
| March 31, 2024 | -$14.94M | +41.6% | -14.6% |
| September 30, 2023 | -$13.04M | +74.1% | -44.9% |
| June 30, 2023 | -$9.00M | -126.4% | +64.9% |
- Akebia Therapeutics, Inc. showed an increase of +146.6% in Operating Income compared to the prior fiscal year.
- Over the 2012–2025 period, Akebia Therapeutics, Inc.’s operating income has grown by 375.7% (from -$8.52 million to $23.50 million).
- The most recent figure is from Akebia Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: